Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): Characterizing the interactions between dot1l and mixed lineage leukemia (MLL) fusion proteins

Journal of Biological Chemistry

Volumn 288, Issue 42, 2013, Pages 30585-30596

  Shen, Chenxi ^a   Jo, Stephanie Y ^a   Liao, Chenzhong ^b   Hess, Jay L ^a   Nikolovska Coleska, Zaneta ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HEFEI UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL TOOLS; FUSION PROTEINS; THERAPEUTIC STRATEGY;

AMINO ACIDS; DISEASES;

PROTEINS;

AF9 PROTEIN; DISRUPTOR OF TELOMERIC SILENCING 1 LIKE; ENL PROTEIN; HISTONE METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; GENE DISRUPTION; GENETIC CONSERVATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

AF9; DOT1L; ENL; FUSION PROTEIN; HISTONE METHYLATION; MIXED LINEAGE LEUKEMIA; PEPTIDES; PROTEIN-PROTEIN INTERACTIONS; SURFACE PLASMON RESONANCE (SPR);

CELL TRANSFORMATION, NEOPLASTIC; HEK293 CELLS; HUMANS; METHYLTRANSFERASES; MUTAGENESIS, SITE-DIRECTED; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN BINDING; TRANSCRIPTIONAL ELONGATION FACTORS;

EID: 84886929228     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.457135     Document Type: Article

References (34)

1. Krivtsov, A. V., and Armstrong, S. A. (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7, 823-833
2. Daser, A., and Rabbitts, T. H. (2004) Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev. 18, 965-974
3. Eguchi, M., Eguchi-Ishimae, M., and Greaves, M. (2003) The role of the MLL gene in infant leukemia. Int. J. Hematol 78, 390-401
4. Ayton, P. M., and Cleary, M. L. (2001) Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20, 5695-5707
5. Biondi, A., Cimino, G., Pieters, R., and Pui, C. H. (2000) Biological and therapeutic aspects of infant leukemia. Blood 96, 24-33
6. Huret, J. L., Dessen, P., and Bernheim, A. (2001) An atlas of chromosomes in hematological malignancies. Example. 11q23 and MLL partners. Leukemia 15, 987-989
7. Slany, R. K. (2005) When epigenetics kills. MLL fusion proteins in leukemia. Hematol. Oncol. 23, 1-9
8. Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., and Zhang, Y. (2005) hDOT1L links histone methylation to leukemogenesis. Cell 121, 167-178
9. Zeisig, D. T., Bittner, C. B., Zeisig, B. B., García- Cuéllar, M. P., Hess, J. L., and Slany, R. K. (2005) The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene 24, 5525-5532
10. Mueller, D., Bach, C., Zeisig, D., Garcia-Cuellar, M. P., Monroe, S., Sreekumar, A., Zhou, R., Nesvizhskii, A., Chinnaiyan, A., Hess, J. L., and Slany, R. K. (2007) A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110, 4445-4454
11. Bitoun, E., Oliver, P. L., and Davies, K. E. (2007) The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum. Mol. Genet. 16, 92-106
12. Yokoyama, A., Lin, M., Naresh, A., Kitabayashi, I., and Cleary, M. L. (2010) A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17, 198-212
13. Biswas, D., Milne, T. A., Basrur, V., Kim, J., Elenitoba-Johnson, K. S., Allis, C. D., and Roeder, R. G. (2011) Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc. Natl. Acad. Sci. U.S.A. 108, 15751-15756
14. Lin, C., Smith, E. R., Takahashi, H., Lai, K. C., Martin-Brown, S., Florens, L., Washburn, M. P., Conaway, J. W., Conaway, R. C., and Shilatifard, A. (2010) AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 37, 429-437
15. Milne, T. A., Martin, M. E., Brock, H. W., Slany, R. K., and Hess, J. L. (2005) Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 65, 11367-11374
16. Krivtsov, A. V., Feng, Z., Lemieux, M. E., Faber, J., Vempati, S., Sinha, A. U., Xia, X., Jesneck, J., Bracken, A. P., Silverman, L. B., Kutok, J. L., Kung, A. L., and Armstrong, S. A. (2008) H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14, 355-368
17. Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., Pollock, R. M., Richon, V. M., Kung, A. L., and Armstrong, S. A. (2011) MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66-78
18. Jo, S. Y., Granowicz, E. M., Maillard, I., Thomas, D., and Hess, J. L. (2011) Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 117, 4759-4768
19. Chang, M. J., Wu, H., Achille, N. J., Reisenauer, M. R., Chou, C. W., Zeleznik-Le, N. J., Hemenway, C. S., and Zhang, W. (2010) Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 70, 10234-10242
20. Nguyen, A. T., Taranova, O., He, J., and Zhang, Y. (2011) DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 117, 6912-6922
21. DelProposto, J., Majmudar, C. Y., Smith, J. L., and Brown, W. C. (2009) Mocr. A novel fusion tag for enhancing solubility that is compatible with structural biology applications. Protein Expr. Purif. 63, 40-49
22. Leach, B. I., Kuntimaddi, A., Schmidt, C. R., Cierpicki, T., Johnson, S. A., and Bushweller, J. H. (2013) Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding. Structure 21, 176-183
23. Schulze, J. M., Wang, A. Y., and Kobor, M. S. (2009) YEATS domain proteins. A diverse family with many links to chromatin modification and transcription. Biochem. Cell Biol. 87, 65-75
24. + channel α. J. Clin. Invest. 117, 773-783
25. Dobson, C. L., Warren, A. J., Pannell, R., Forster, A., Lavenir, I., Corral, J., Smith, A. J., and Rabbitts, T. H. (1999) The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J. 18, 3564-3574
26. Slany, R. K., Lavau, C., and Cleary, M. L. (1998) The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol. Cell Biol. 18, 122-129
27. Zhang, W., Xia, X., Reisenauer, M. R., Hemenway, C. S., and Kone, B. C. (2006) Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaC+ in an aldosterone-sensitive manner. J. Biol. Chem. 281, 18059-18068
28. Srinivasan, R. S., Nesbit, J. B., Marrero, L., Erfurth, F., LaRussa, V. F., and Hemenway, C. S. (2004) The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells. Leukemia 18, 1364-1372
29. Min, J., Feng, Q., Li, Z., Zhang, Y., and Xu, R. M. (2003) Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 112, 711-723
30. Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., Jin, L., Kuntz, K. W., Chesworth, R., Moyer, M. P., Bernt, K. M., Tseng, J. C., Kung, A. L., Armstrong, S. A., Copeland, R. A., Richon, V. M., and Pollock, R. M. (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65
31. Bernt, K. M., and Armstrong, S. A. (2011) A role for DOT1L in MLLrearranged leukemias. Epigenomics 3, 667-670
32. Feng, Y., Yang, Y., Ortega, M. M., Copeland, J. N., Zhang, M., Jacob, J. B., Fields, T. A., Vivian, J. L., and Fields, P. E. (2010) Early mammalian erythropoiesis requires the Dot1L methyltransferase. Blood 116, 4483-4491
33. Jones, B., Su, H., Bhat, A., Lei, H., Bajko, J., Hevi, S., Baltus, G. A., Kadam, S., Zhai, H., Valdez, R., Gonzalo, S., Zhang, Y., Li, E., and Chen, T. (2008) The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet. 4, e1000190
34. Nguyen, A. T., and Zhang, Y. (2011) The diverse functions of Dot1 and H3K79 methylation. Genes Dev. 25, 1345-1358